SEC 13F Intelligence

Managers / Q1 2022 · view latest →

EcoR1 Capital, LLC

CIK 0001587114 · 357 TEHAMA STREET #3, SAN FRANCISCO, CA, 94103 · 415-448-6534

Reported Value
$3.2B
Q1 2022
Positions
87
Filings on Record
32
2019–present window
Filed
May 16, 2022
original filing

Summary

Ecor1 Capital, LLC reported $3.2B in U.S.-listed holdings across 87 positions for Q1 2022.

Its largest position, Prothena, represents 13.3% of the portfolio.

Compared with Q4 2021, the fund opened 22 new positions and exited 10.

Portfolio Metrics

Turnover
+33.6%
vs prior filed quarter
Top-10 Concentration
+58.8%
share of reported value
Largest Position
+13.3%
Prothena
New / Exited
22 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $999MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $990MQ3 ’19: $792MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $957MQ2 ’20: $1.4BQ3 ’20: $1.4BQ4 ’20: $1.9BQ4 ’20Q1 ’21: $2.3BQ2 ’21: $2.7BQ3 ’21: $2.9BQ4 ’21: $3.1BQ4 ’21Q1 ’22: $3.2BQ2 ’22: $2.9BQ3 ’22: $3.4BQ4 ’22: $3.3BQ4 ’22Q1 ’23: $3.1BQ2 ’23: $4.1BQ3 ’23: $3.0BQ4 ’23: $3.9BQ4 ’23Q1 ’24: $4.0BQ2 ’24: $3.3BQ3 ’24: $2.9BQ4 ’24: $2.6BQ4 ’24Q1 ’25: $1.7BQ2 ’25: $1.7BQ3 ’25: $2.1BQ4 ’25: $2.2BQ4 ’25Q1 ’26: $2.4Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 73.0%Other: 15.5%ADR: 11.4%Equity WRT: 0.2%
  • Common Stock · 73.0% · $2.3B
  • Other · 15.5% · $496M
  • ADR · 11.4% · $363M
  • Equity WRT · 0.2% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRPTSAREPTA THERAPEUTICS INCNEW+2.07M2.07M+$162M$162M
ZLABZAI LAB LTDNEW+2.22M2.22M+$98M$98M
RETAEURREATA PHARMACEUTICALS INCNEW+1.98M1.98M+$65M$65M
CEREVEL THERAPEUTICS HLDNG INEW+1.65M1.65M+$58M$58M
MRTXEURMIRATI THERAPEUTICS INCNEW+500.6K500.6K+$41M$41M
ARGXARGENX SENEW+125.0K125.0K+$39M$39M
RVMDREVOLUTION MEDICINES INCNEW+1.27M1.27M+$33M$33M
BCYCBICYCLE THERAPEUTICS PLCNEW+547.5K547.5K+$24M$24M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1PROTHENA CORP PLCSHS13.25%$424M11.58M
2APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM8.24%$263M5.18M
3GALAPAGOS NVSPON ADR6.20%$198M3.20M
4ANABANAPTYSBIO INChistory →COM5.82%$186M7.52M
5SRPTSAREPTA THERAPEUTICS INChistory →COM5.06%$162M2.07M
6MORFUSDMORPHIC HLDG INChistory →COM4.96%$159M3.95M
7ACADACADIA PHARMACEUTICALS INChistory →COM4.54%$145M5.99M
8XNCRXENCOR INChistory →COM4.15%$133M4.97M
9KURAKURA ONCOLOGY INChistory →COM3.34%$107M6.64M
10RCUSARCUS BIOSCIENCES INChistory →COM3.22%$103M3.27M
11ARVNARVINAS INChistory →COM3.17%$101M1.50M
12ZLABZAI LAB LTDhistory →ADR3.06%$98M2.22M
13ALECALECTOR INChistory →COM2.56%$82M5.74M
14NUVBNUVATION BIO INChistory →COM CL A2.29%$73M13.90M
15RLAYRELAY THERAPEUTICS INChistory →COM2.15%$69M2.29M
16RETAEURREATA PHARMACEUTICALS INChistory →CL A2.02%$65M1.98M
17TSVT*2SEVENTY BIO INChistory →COMMON STOCK1.87%$60M3.50M
18CEREVEL THERAPEUTICS HLDNG ICOM1.80%$58M1.65M
19RNAGBPAVIDITY BIOSCIENCES INChistory →COM1.59%$51M2.76M
20AVIRATEA PHARMACEUTICALS INChistory →COM1.43%$46M6.34M
21MRTXEURMIRATI THERAPEUTICS INChistory →COM1.29%$41M500.6K
22ARGXARGENX SEhistory →SPONSORED ADR1.23%$39M125.0K
23DSGNDESIGN THERAPEUTICS INChistory →COM1.20%$38M2.37M
24RVMDREVOLUTION MEDICINES INChistory →COM1.02%$33M1.27M
25PCVXVAXCYTE INChistory →COM0.99%$32M1.30M
26VYGRVOYAGER THERAPEUTICS INChistory →COM0.85%$27M3.56M
27BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS0.75%$24M547.5K
28EWTXEDGEWISE THERAPEUTICS INChistory →COM0.72%$23M2.36M
29EX9EXELIXIS INChistory →COM0.67%$22M951.3K
30JANXJANUX THERAPEUTICS INChistory →COM0.64%$20M1.42M
31GONGERON CORPhistory →COM0.61%$19M14.29M
32OVIDOVID THERAPEUTICS INChistory →COM0.60%$19M6.12M
33SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM0.58%$18M325.9K
34ORICORIC PHARMACEUTICALS INChistory →COM0.57%$18M3.42M
35VTYXUSDVENTYX BIOSCIENCES INChistory →COM0.55%$18M1.30M
36CRNXCRINETICS PHARMACEUTICALS INhistory →COM0.54%$17M790.2K
37ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM0.54%$17M895.5K
38SURFUSDSURFACE ONCOLOGY INChistory →COM0.43%$14M4.65M
39PMVPPMV PHARMACEUTICALS INChistory →COM0.42%$14M649.8K
40HOOKIPA PHARMA INCCOM0.36%$11M5.00M
41CHINOOK THERAPEUTICS INCCOM0.35%$11M690.0K
42AKOUOS INCCOM0.29%$9M1.98M
43PTGXPROTAGONIST THERAPEUTICS INCCOM0.28%$9M381.7K
44ALIGOS THERAPEUTICS INCCOM0.27%$8M3.95M
45NGM BIOPHARMACEUTICALS INCCOM0.26%$8M541.1K
461K0IGM BIOSCIENCES INCCOM0.25%$8M298.6K
47ERASERASCA INCCOM0.18%$6M678.4K
48FRAZIER LIFESCIENCES ACQU CO CL ASHS0.18%$6M587.6K
49TNGXTANGO THERAPEUTICS INCCOM0.18%$6M762.0K
50ZNTLZENTALIS PHARMACEUTICALS INCCOM0.17%$5M115.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.4B30May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.2B30Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$2.1B30Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.7B37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.7B46May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$2.6B59Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.9B64Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$3.3B55Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$4.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$3.9B51Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3.0B51Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$4.1B53Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$3.1B58May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$3.3B66Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.4B76Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.9B80Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$3.2B87May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$3.1B76Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B71Nov 22, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$2.7B72Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.3B71May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.9B67Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.4B50Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.4B49Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$957M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B44Feb 18, 2020RESTATEMENTchanges · EDGAR ↗
Q3 2019$792M41Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$990M40Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B41May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$999M54Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.